Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma
The provided text discusses the challenges and treatments associated with relapsed/refractory multiple myeloma (RRMM). It highlights the impact on health-related quality of life, treatment outcomes, and the use of patient-reported outcome measures in evaluating the disease. The study focuses on the safety and effectiveness of belantamab mafodotin, an antibody-drug conjugate, in the treatment of RRMM. It details the study design, patient-reported outcomes, and the impact of corneal events on vision-related functioning. The analysis underscores the importance of PRO data in providing insights for patient counseling and decision-making.
1. Multiple myeloma (MM) is a relapsing, incurable hematologic cancer.2. Belantamab mafodotin has shown deep and durable responses in patients with triple-class refractory RRMM.3. Patient-reported outcome measures provide direct insights into patient experiences with novel therapies in MM.4. The study details the impact of corneal events on vision-related functioning and HRQOL of patients with MM.5. The analysis emphasizes the value of PRO data in counseling patients and supporting treatment decisions.
Listen Tab content
